Alan Miller, MD
Internal Medicine · Peachtree Corners, GANPI 1508815606
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,328 of the $45,350 with a category attached, or 97.7%. AstraZeneca accounts for 94.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $42,692 and has fallen 97.8% since, to $933 in 2023. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $3023.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43K
- Bayer$2K
- Novartis$898
- Boston Scientific$90
- Amgen$35
Across 234 payments — averaging $9705.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$840K
- Amgen$645K
- Novartis$356K
- Kowa Research Institute, Inc.$190K
- AstraZeneca$106K
- Esperion Therapeutics, Inc.$103K
- plus $31K from 4 others
What the payments were for
- Consulting fees$44,32898%
- Travel & lodging$3561%
- Food & beverage$6661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $42,692 |
| Bayer | 1 | $1,636 |
| Novartis | 8 | $898 |
| Boston Scientific | 2 | $90 |
| Amgen | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$1,636
- LEQVIO$569
How this compares
$45,350 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 22 | $32,636 |
| TrulicityDulaglutide | 11 | $29,226 |
| XareltoRivaroxaban | 38 | $5,235 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,972 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $1,864 |
| Metformin Hcl ErMetformin Hcl | 89 | $1,545 |
| Atorvastatin Calcium | 202 | $1,531 |
| Levothyroxine Sodium | 187 | $1,438 |
| Rosuvastatin Calcium | 96 | $1,182 |
| Lisinopril | 164 | $784 |
| Glimepiride | 91 | $755 |
| Irbesartan | 30 | $636 |
| Losartan Potassium | 78 | $477 |
| Ezetimibe | 31 | $466 |
| Allopurinol | 48 | $461 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Peachtree Corners
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.